 "Clariant to acquire a part of Vivimed Labs' personal care portfolio")
Swiss specialty chemicals major Clariant on September 29, 2015 entered into an agreement to acquire a part of Vivimed Labs Limited’s personal care portfolio. The transaction values the identified products, trademarks and related assets of Vivimed at Rs 380 crore. The acquisition will enable Clariant India Ltd (a wholly-owned subsidiary of Clariant Group) to strengthen its personal care portfolio within the industrial & consumer specialties (ICS) business, by offering a wider product portfolio within the sun, skin, hair and oral care range as well as anti-microbial preservatives.
“The personal care industry in India offers us immense potential supported by the growing middle-class consumer population and the rising disposable income. This strategic decision will be a significant step towards strengthening our product portfolio and thereby reinforcing Clariant’s long term commitment in the segment. We believe in the growth potential that India offers and are focussed on expanding our footprint in the region,” commented Dr Deepak Parikh, region president - India, Middle East and Africa, Clariant.
Stephen Lynen, head ICS, Asia Pacific, Clariant, said, “This marks an important step of our global strategy to enhance our offering in personal care and to boost our presence in Asia. The transaction will strengthen our portfolio with actives to formulate broader solutions such as sun protection in a strong growing market – India.”
This acquisition will enable Clariant to expand its footprint and provide its customers with end-to-end solutions in sync with the current industry trends. “The strong growth perspective of the personal care industry results in a bright future for the ICS business in India,” added R Kumaresan, head of Clariant’s BU ICS, India.
Santosh Varalwar, MD & CEO, Vivimed Labs Limited, said, “I am pleased to announce an important strategic development at Vivimed. This transaction will help us significantly improve our financial flexibility for future growth. We are confident that this transaction, once completed, will position Vivimed optimally to move to the next level of growth, across its specialty chemicals and pharmaceuticals businesses.”
Clariant India operates in four business areas - care chemicals, catalysis & energy, natural resources, and plastics & coatings, including businesses like pigments (coatings, printing and plastics and special applications), additives, industrial & consumer specialties, mining services and masterbatches. In 2014, Clariant invested in a regional innovation centre in Mumbai, with an aim to co-create tailor-made solutions with customers for the industry.
“The personal care industry in India offers us immense potential supported by the growing middle-class consumer population and the rising disposable income. This strategic decision will be a significant step towards strengthening our product portfolio and thereby reinforcing Clariant’s long term commitment in the segment. We believe in the growth potential that India offers and are focussed on expanding our footprint in the region,” commented Dr Deepak Parikh, region president - India, Middle East and Africa, Clariant.
Stephen Lynen, head ICS, Asia Pacific, Clariant, said, “This marks an important step of our global strategy to enhance our offering in personal care and to boost our presence in Asia. The transaction will strengthen our portfolio with actives to formulate broader solutions such as sun protection in a strong growing market – India.”
This acquisition will enable Clariant to expand its footprint and provide its customers with end-to-end solutions in sync with the current industry trends. “The strong growth perspective of the personal care industry results in a bright future for the ICS business in India,” added R Kumaresan, head of Clariant’s BU ICS, India.
Santosh Varalwar, MD & CEO, Vivimed Labs Limited, said, “I am pleased to announce an important strategic development at Vivimed. This transaction will help us significantly improve our financial flexibility for future growth. We are confident that this transaction, once completed, will position Vivimed optimally to move to the next level of growth, across its specialty chemicals and pharmaceuticals businesses.”
Clariant India operates in four business areas - care chemicals, catalysis & energy, natural resources, and plastics & coatings, including businesses like pigments (coatings, printing and plastics and special applications), additives, industrial & consumer specialties, mining services and masterbatches. In 2014, Clariant invested in a regional innovation centre in Mumbai, with an aim to co-create tailor-made solutions with customers for the industry.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%